AUTHORS
Seyram Adzraku, PhD, Kayleigh Omdahl, Ph.D.2, Sunil Poudel, PhD3, Matthew D'Ambra, BA4, Yigeng Cao II, MD, PhD5, Yujie Zhao6, Bruce Blazar, MD, PhD7, Leslie Kean, MD, PhD8, Victor Tkachev, PhD9
AFFILIATIONS
1 Massachusetts General Hospital, Boston, Massachusetts, United States
2 Boston Children's Hospital, Boston, Massachusetts, United States
3 Massachusetts General Hospital, Boston, Massachusetts, United States
4 Massachusetts General Hospital, Boston, Massachusetts, United States
5 Massachusetts General Hospital, Boston, Massachusetts, United States
6 University of Minnesota, Minneapolis, Minnesota, United States
7 University of Minnesota, Minneapolis, Minnesota, United States
8 Boston Children's Hospital, Boston, Massachusetts, United States
9 Massachusetts General Hospital, Boston, Massachusetts, United States
ABSTRACT
Acute GVHD is a major barrier to success after alloHCT, and patients with gastrointestinal (GI) disease often poorly respond to treatment and have inferior survival. In our previous work, using a model in rhesus macaques, we discovered that circulating donor effector-memory T cells (Tem) infiltrate the recipient’s small and large intestines early after alloHCT and acquire tissue-resident memory (Trm) phenotype, important for propagating GI aGVHD (Tkachev et al, Sci Tranl Med, 2021). Trm cells are associated with upregulation of Regulator of G-protein Signaling-1 (Rgs1) that attenuates G-protein coupled receptors and restrains Trm egress from the GI tract, thereby contributing to in situ immune responses. Together with the recent data on the role of Rgs1 in maintenance of murine intestinal Trm cells post-infection (von Werdt, Front Immunol, 2023), we hypothesize that Rgs1 expression will augment GI aGVHD pathogenesis.
To test this hypothesis, we transplanted C57Bl6 (B6, H-2b) T cells from wild-type (WT) or Rgs1 knockout (Rgs1KO) donors, together with B6 BM graft to semi-allogeneic, MHC-mismatched BDF1 (B6xDBA/2 F1; H-2b/d). We found that Rgs1KO donor T cells induced less severe aGVHD, reflected by lower combined clinical score starting on day 28 after alloHCT, and improved survival (mean survival time (MST) = 81 days in Rgs1KO vs 37.5 days in WT group, p<0.01). Mechanistically, we determined that Rgs1KO T cells displayed normal alloantigen(alloAg)-driven proliferation by in vitro in allogeneic mixed lymphocyte reaction and in vivo across all tested organs (spleen, liver, mesenteric lymph nodes (mLN), and GI tract). In aggregate, donor T cell Rgs1 loss did not impair T cell alloreactivity. On day 4 post-transplant, equivalent splenic and mLN GI-homing receptors (a4b7 integrin, Ccr9, and GPR15) and retrieved donor T cell numbers in the colon and ileum were observed in recipients of donor WT and Rgs1KO CD4 and CD8 T cells. While Rgs1 was dispensable for the initial (day 4) donor T cell seeding of GI organs after alloHCT, at a later stage (day 21), a substantially lower frequency of donor CD69+CD103+ CD8 Trm cells was seen in the ileum (16.1 ± 5.2 % in Rgs1KO vs 33.2 ± 11.6 % in WT, p<0.05) and colon (6.3 ± 1.9 % vs 12.0 ± 3.9 %, respectively, p<0.05). At this later time, the lower frequency of Rgs1 KO CD8 Trm T cells translated into lower absolute numbers recovered from these organs compared to WT controls (ileum: 98.4 ± 43.6 vs 314.3 ± 126.0, colon: 16.2 ± 4.7 vs 38.5 ± 12.3; all × 103, p<0.05). In contrast, the frequencies/number of other T cell subtypes in the gut were comparable between groups. The defect in intestinal retention of Rgs1KO Trm on day 21 was concurrent with reduced GVHD clinical manifestations compared with WT T cells. Loss of Rgs1 did not impair CD69+CD103+ Trm-like differentiation of spleen T cells driven by Trm-instructive cytokines in vitro, suggesting that the retention of Trm cells or their precursors after initial day 4 seeding of the GI tissues is the main mechanism of the observed decrease in donor Trm frequency/number in the gut on day 21 after alloHCT. Despite ameliorated GVHD effects, Rgs1KO T cells cleared tumor P815 cells in all BDF1 alloHCT recipients (n=16 total in 2 experiments) and killed a slightly higher number of P815 in vitro (43.4 ± 11.0 vs 26.6 ± 6.6 in the WT group at the 10:1 T:target ratio, p=0.04). Collectively, these data indicate GVHD attenuation with unimpaired GVL activity.
To assess translational potential, the RGS1 gene was edited by CRISPR/Cas9 in human T cells. Consistent with murine GVHD results, RGS1-edited human T cells caused less severe GVHD upon xenogeneic transplantation to immunodeficient NSG mice in two independent experiments. In an initial experiment, the MST of RGS1-edited group (n=10) was 30 vs 16 days in the mock-edited control (n=10), p<0.01. These results were reproduced in a second experiment with a different healthy donor as evidenced by a longer MST = >100 vs 72 days, p<0.05, in recipients of RGS1- vs. mock-edited T cells (n=5 in both groups). Both RGS1- and mock-edited human T cells displayed normal alloAg-driven proliferation in an MLR assay and intact killing of allogeneic tumor cells across different T:target cell ratios. Together, our results demonstrate that Rgs1 deficiency influences GI aGVHD pathogenesis by reducing donor Trm retention within the gut, findings that can represent a novel therapeutic target for separating aGVHD from GVL effect.
DISCLOSURES
Seyram Adzraku, PhD: No relevant conflicts of interest to declare.